With its first major drug rollout looming, FibroGen, a San Francisco-based biotech, has tapped a Big Pharma veteran to be its new CEO.
The company announced this week that Enrique Conterno will join the company as its CEO. Conterno, who’s worked in pharma for 27 years, recently stepped down from his big-time role as the president of Ely Lilly’s diabetes division in the U.S. FibroGen’s former CEO, Thomas B. Neff, passed away unexpectedly in August.
In his new role, Conterno will be tasked with helping lead FibroGen through the commercial rollout of the most advanced treatment in its pipeline: roxadustat, an anemia drug for patients with chronic kidney disease. Roxadustat has already been given the go-head in China and Japan, and the company submitted its marketing application to the FDA in late 2019.
Conterno has been credited with helping Lilly gain the industry’s top spot in the diabetes market. Given his vast experience with diabetes, FibroGen is banking on his know-how in the world of kidney and metabolic diseases.
Read the press release.
